Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies. However, prominent names in this fast-growing space have seen their shares soar in the past two years, and the valuations of some have become quite expensive.Two AI healthcare stocks -- Recursion Pharmaceuticals (NASDAQ: RXRX) and Teladoc Health (NYSE: TDOC) -- have lagged the market over the past year. But if these companies' ambitions (AI-related and otherwise) materialize over the long run, they could deliver market-beating returns. Are the stocks worth investing in?Recursion Pharmaceuticals is using AI to speed up the slow and expensive process of drug discovery and development.Continue reading
Artificial intelligence (AI) is changing the world. Corporations are racing to establish themselves as leaders in the field, while investors want to cash in by putting their hard-earned money into the most promising AI companies. However, prominent names in this fast-growing space have seen their shares soar in the past two years, and the valuations of some have become quite expensive.
Two AI healthcare stocks -- Recursion Pharmaceuticals (NASDAQ: RXRX) and Teladoc Health (NYSE: TDOC) -- have lagged the market over the past year. But if these companies' ambitions (AI-related and otherwise) materialize over the long run, they could deliver market-beating returns. Are the stocks worth investing in?
Recursion Pharmaceuticals is using AI to speed up the slow and expensive process of drug discovery and development.
